Ajmal Biotech Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 11-12-2024
- Paid Up Capital ₹ 1.10 Cr
as on 11-12-2024
- Company Age 19 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 89.59%
(FY 2022)
- Profit 65.90%
(FY 2022)
- Ebitda -69.51%
(FY 2022)
- Net Worth 21.87%
(FY 2022)
- Total Assets 25.79%
(FY 2022)
About Ajmal Biotech
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.10 Cr, as per Ministry of Corporate Affairs (MCA) records.
Mohammed Ajmal and Mohammed Ajmal serve as directors at the Company.
- CIN/LLPIN
U24239MH2005PTC223597
- Company No.
223597
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Sep 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Ajmal Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mohammed Ajmal  | Director | 02-Sep-2005 | Current |
| Mohammed Ajmal | Director | 02-Sep-2005 | Current |
Financial Performance of Ajmal Biotech.
Ajmal Biotech Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 89.59% increase. The company also saw a substantial improvement in profitability, with a 65.9% increase in profit. The company's net worth Soared by an impressive increase of 21.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ajmal Biotech?
In 2022, Ajmal Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Flower Valley Agro-Tech Private LimitedActive 29 years 9 months
Mohammed Ajmal and Mohammed Ajmal are mutual person
- Flower Valley Perfumes Private LimitedActive 30 years
Mohammed Ajmal and Mohammed Ajmal are mutual person
- Al-Majid Distillation And Processing Private LimitedActive 23 years 30 days
Mohammed Ajmal is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ajmal Biotech?
Ajmal Biotech has a workforce of 12 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ajmal Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ajmal Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
